FebriDx® Receives Updated CE Mark to Allow Incorporation of All-in-One Test Format
RPS Diagnostics, Inc. (RPS®) today announced an updated CE mark of its FebriDx® test, clearing the way for its immediate launch in the European Union and all countries recognizing the CE mark. FebriDx is a rapid, accurate, and simple to use point-of-care test that is expected to contribute towards a diagnostic solution to the global antibiotic crisis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181030006130/en/
RPS Diagnostics' FebriDx test. (Photo: Business Wire)
FebriDx provides clinicians with a 10-minute assessment of the body’s immune response to an acute respiratory infection (ARI) directly from a fingerstick blood sample. The single use, disposable test identifies patients who have a clinically significant underlying infection and aids in the differentiation of viral and bacterial ARIs through the rapid detection of both Myxovirus resistance protein A (MxA) and C-reactive protein (CRP). MxA is an intracellular protein that becomes elevated in the presence of acute viral infection and CRP is a nonspecific inflammatory protein that is elevated in the presence of any clinically significant infection. Thus, unlike a standalone CRP test, MxA confers specificity to the test through the combined interpretation of the results.
The updated FebriDx test incorporates an all-in-one plastic housing technology that includes a built-in safety lancet, blood collection and delivery system, and integrated push button buffer delivery feature, which together, improve test convenience. The FebriDx test requires no additional equipment to perform or to interpret results. Through comprehensive analytical testing as well as a multicenter precision and reproducibility study, RPS Diagnostics successfully demonstrated equivalency to the previously CE marked version of the product. “Obtaining the updated CE mark triggers the initial international commercial launch of the FebriDx test,” said Robert Sambursky, MD, president and chief executive officer of RPS. “This test will provide a cost effective outpatient solution to improve antimicrobial stewardship.”
The timely FebriDx test results provide clinicians the ability to formulate a targeted clinical management and therapeutic decision plan during the initial patient encounter. Antibiotic misuse is a complex global problem that leads to antibiotic resistance, avoidable adverse events, and contributes to rising healthcare costs, largely driven by diagnostic uncertainty and patient pressure. More than 50% of all antibiotic prescriptions are unnecessary and are generated in the outpatient primary and urgent care setting. In a recent study in the United Kingdom, FebriDx was shown to alter clinical management decisions in 48% of patients tested, and to reduce unnecessary antibiotic prescriptions by 80%. Each day that goes by without the implementation of a cost effective solution is exacerbating the current global antibiotic crisis.
“The elegance of the FebriDx test lies in its simplicity,” said Robert Sambursky, MD. “It’s equally important not to miss treating an underlying bacterial infection as it is withholding unnecessary antibiotics from patients with clinically insignificant or viral infection. While most research and investment over the past decade has focused on rapid molecular testing to identify specific pathogens, FebriDx utilizes the body’s own immune system to provide a broad, fast, accurate, and cost-effective method to identify patients who may benefit from appropriate antibiotic therapy.”
For more information about the FebriDx test, visit FebriDx.com.
RPS Diagnostics (RPS) is an emerging developer, manufacturer, and marketer of cost-effective point-of-care (POC) tests for systemic infectious disease and antibiotic stewardship. The company’s innovative and patented FebriDx® test is a rapid, disposable, in-office test that uses a fingerstick blood sample to help identify a clinically significant immune response and differentiate bacterial from viral causes for fever in acute respiratory infection. With a 97% negative predictive value, FebriDx delivers results in 10 minutes and can be used to help triage infectious patients during the initial office visit, providing clinicians with actionable information that can be used to limit unnecessary antibiotics. At this time, the FebriDx test has not received U.S. Food and Drug Administration (FDA) clearance and is not commercially available in the United States. For more information on RPS and its products, visit RPSdetectors.com.
For RPS Diagnostics
Laura Lovejoy Sambursky, 1 941-928-9025
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Cloudreach Gets Closer to its Nordic Customers With Presence in Stockholm, Sweden19.3.2019 08:00:00 CET | Pressemelding
Cloudreach, a global, cloud-native solutions provider, has announced today that it will be establishing a new base in Stockholm, Sweden. The new location will enable customers in the Nordic region to accelerate their transformation journey with enhanced service and support from Cloudreach locally. The Nordics are rapidly becoming a key market for Cloudreach, and the company already has high-profile clients in the region. Home to many well-known brands and global corporations, the Nordics have also shown a particular appetite for cloud computing services in recent years, with Finland, Sweden and Denmark leading the way in cloud adoption. The opportunities in the cloud market have been noticed by the major Cloud Service Providers, with AWS, Azure and GCP choosing Sweden, Norway and Finland respectively, as the locations for their data centres in the region. “I'm delighted to confirm Cloudreach's commitment to supporting both existing and new customers, locally with our expansion into the
Mobidiag to Attend the 29th European Congress of Clinical Microbiology & Infectious Diseases in Amsterdam, the Netherlands19.3.2019 07:00:00 CET | Pressemelding
Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, will be attending the 29th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Amsterdam, the Netherlands, from 13-16 April 2019. Organised by Europe’s leading society in clinical microbiology and infectious diseases, the ECCMID annual meeting brings together leading experts from around the world, including innovative commercial companies specializing in diagnostics. Mobidiag will be hosting an Exhibit Booth (#1.62, Hall 3) at ECCMID. The Company will demonstrate its proprietary diagnostic solutions, Amplidiag® and Novodiag® and showcase how these can be used to provide fast, accurate and accessible solutions for the diagnosis of infectious diseases and, particularly in antimicrobial resistance. Mobidiag has made significant progress in recent months, including: Mobidiag Joint Venture with Autobio Diagnostics and €10m equity investment (17/12/18) M
Western Union Teams Up with Thunes to Expand Payout Capabilities to Mobile Wallets19.3.2019 01:00:00 CET | Pressemelding
Western Union (NYSE: WU), a leader in cross-border, cross-currency money movement, has teamed up with Thunes, a cross-border payments network for emerging markets, to enable Western Union customers to send funds directly into mobile wallets around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190318005639/en/ Senders can now utilise Western Union’s growing digital network or an agent location to send funds directly into a recipient’s mobile wallet. “We are continuously expanding and enhancing our account payout portfolio, providing customers with multiple payout options including bank accounts, cards or mobile wallets,” said Sobia Rahman, Global Head of Account Payout Network for Western Union. “Our goal is to make digital money transfer services more accessible, with a specific focus on enabling mobile transactions.” The collaboration will enable greater financial access for consumers - especially those who lack
Velodyne Demonstrates Lidar Solution for Rich Perception Data Collection on NVIDIA DRIVE Platform19.3.2019 01:00:00 CET | Pressemelding
Velodyne Lidar, Inc. today announced its surround-view lidar solutions for collecting rich perception data in testing and validation are available on the NVIDIA DRIVE™ autonomous driving platform--allowing full, 360-degree perception in real time, facilitating highly accurate localization and path-planning capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190318005791/en/ Proven through learning from millions of road miles, Velodyne sensors help determine the safest way to navigate and direct a self-driving vehicle. (Photo: Business Wire) Velodyne sensors’ characteristics are also available on NVIDIA DRIVE Constellation™, an open, scalable simulation platform that enables large-scale, bit-accurate hardware-in-the-loop testing of AVs. The solution’s DRIVE Sim™ software simulates lidar and other sensors, recreating a self-driving car’s inputs with high fidelity in the virtual world. “Velodyne and NVIDIA are at the f
Kohler Celebrates the Details of Design at Milan Design Week 201919.3.2019 00:22:00 CET | Pressemelding
Kohler, a global lifestyle brand, returns to Milan Design Week to host an enticing sensory experience inside the historic Palazzo Del Senato (via Senato, 10, 20121 Milan, Italy). The large-scale immersive exhibit showcases Kohler’s bold approach to design and the brand’s most stunning products through an artful combination of water, technology, texture, and color. The installation will be open April 9 through April 13 from 10am – 7pm daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190318005858/en/ The large-scale immersive exhibit showcases Kohler’s bold approach to design and the brand’s most stunning products through an artful combination of water, technology, texture, and color. The installations feature global debuts of products from KOHLER, KALLISTA, ANN SACKS and ROBERN. (Photo: Business Wire) “Milan Design Week is the ultimate celebration of creativity and innovation among the global design community,” said Jim
ams and Wise Road Capital Advance Further Development for Environmental, Flow and Pressure Sensors Through Creation of a Joint Venture19.3.2019 00:09:00 CET | Pressemelding
ams (SIX: AMS), a leading worldwide supplier of high performance sensor solutions, and Wise Road Capital, a global Private Equity firm focusing on the semiconductor industry and other emerging high-tech industries, announce today that they have signed an agreement to create a joint venture to advance the development and sales of environmental, flow and pressure sensor solutions for the global market. Under the agreement, employees, IP, sensor products and solutions and related customers will transfer from ams to the joint venture, while Wise Road Capital will provide its expert joint venture guidance, deep market knowledge and strength in channel and customer relationships, especially in China. ams will transfer its current environmental sensor solution portfolio covering air quality, relative humidity and temperature sensing, which are used in automotive, smart building and air quality monitoring infrastructure applications. In addition, the ams ultrasound-based flow sensor solutions,